Author Page for Beilei Wang

Actions:

View:
Selected
Original List
All Versions Hide All Versions
All Abstracts Hide All Abstracts

(Rank)

Repurposing of Clinical-Stage Flt3 Inhibitor Hyml-122 as a Potent Ripk2 Inhibitor for the Treatment of Inflammatory Bowel Disease

Number of pages: 50 Posted: 13 Feb 2025

Jie Hu, Juan Liu, Fengming Zou, Xixiang Li, Hongwei Yu, Beilei Wang, Li Wang, Jun Tang, Xilu Hou, Qian Gao, Jiaoxue Wang, Xing He, Yanjie Chen, Hezhong Yan, Jing Liu, Aoli Wang, Wenchao Wang and Qingsong Liu

affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN

Downloads 88 (765,566)

Beilei Wang

affiliation not provided to SSRN

1

88

0

Scholarly Papers (1)

Repurposing of Clinical-Stage Flt3 Inhibitor Hyml-122 as a Potent Ripk2 Inhibitor for the Treatment of Inflammatory Bowel Disease

Abstract: